Meet Our Editorial Board Member Current Aging Science, 2017, Vol

Meet Our Editorial Board Member Current Aging Science, 2017, Vol. 10, No. 3 157 Meet Our Editorial Board Member Prof. Moussa B.H. Youdim Technion-Rappaport Family-Faculty of Medicine Haifa, Israel

Prof. Moussa Youdim was the chairman department of Pharmacology from its inception, in 1977 to 1994. He was the Finkelstein Professor of Life Sciences and Professor of Pharmacology at the Technion-Rappaport Family Faculty of Medicine. He is the Professor Emeritus and the Director of the Eve Topf and National Parkinson Foundation (USA) Centers of Excellence for Neurodegenerative Diseases Research and Teaching at Technion. He holds the position of Honorary Professor and Distin- guished Chair Professor at Hong Kong and PolyTechnic Universities in Hong Kong, Yonsei World Central University in Seoul, South Korea; Qingdao University and Shanghai University of Chinese Traditional Medicine in China and Janin University in China. He is internationally renowned for his research on monoamine oxidases, brain iron metabolism, Parkinson’s Disease (PD), Alzheimer’s Disease (AD), amyotrophic lateral sclerosis and drug development for these disorders and for highlighting the im- portance of monoamine oxidase and brain iron metabolism for brain function and dysfunction. His research at Oxford Univer- sity led to the discovery of the first monoamine oxidase B inhibitor, l-deprenyl (selegiline) as an anti-Parkinson drug, in 1975, and the concept of neuroprotection. At Technion, he developed the second generation of neuroprotective monoamine oxidase B inhibitor anti-Parkinson drug, Rasagiline (Azilect) with John Finberg. He developed the first multifunctional neuroprotective anti-Alzheimer drug, currently designated Ladostigil (TV 3326), which has recently shown positive results in Phase IIb double blind control clinical studies in Alzheimer patients MCI and novel multi target neurorestorative M30 iron chelator series which are under development for Parkinson's and Alzheimer's diseases in his company Abital Pharma Pipeline Ltd. He has more than 100 drug patents, and more than 900 scientific articles to his credit, edited 45 books and has been the Edi- torial Board Member of 43 International Scientific Journals. He has received numerous (40) major international prizes, awards and honors from Iran (Homayoon Medal from Shah of Iran), Israel, U.S., England, Germany, Denmark, Holland and Switzer- land, including two Honorary Doctorate of Philosophy, Honoris Causa, from the universities of Semmelweis University (Hun- gry) and Pisa (Italy). From 1991 through 1999, he was a Fogarty International Scholar-in-Residence at the Fogarty International Center for Ad- vanced Study in the Human Health Sciences program of the National Institute of Health in Bethesda, USA. He is the scientific founder of Varinel Inc. and Varinel LCD (USA) Cardiamit, Avraham Pharmaceutical (Israel) and the Chief Scientific Officer of Abital Pharma Pipeline Ltd. (Israel). He is an elected member of Leopoldina German Academy of Sciences, the oldest academy in the world and Hugarian Academy of Sciences. He was recently awarded ECNP (European College of Neuropsycho- pharamacolgy) Lifetime Achievement Award, the EMET prize for brain science from Israel, CINP (International College of Neuropschopharmacology) Pioneering Award, the Arvid Carlson Metal and The Catecholamine Pioneering Award from NIH and 10th International Congress of Catecholamine. He was recently elected as an Honorary Member of Israel Society for Neuro- science for his fundamental contribution to neuroscience.

SELECTED PUBLICATIONS

[1] Einoch R, Weinreb O, Mandiuk N, Youdim MBH, Bilker W, Silver H. The involvement of BDNF-CREB signaling pathways in the pharmacological mechanism of combined SSRI-antipsychotic treatment in schizophrenia. Eur Neuropsychopharmacol 2017; 27(5): 470-83. [2] Liu W, Rabinovich A, Nash Y, et al. Anti-inflammatory and protective effects of MT-031, a novel multitarget MAO-A and AChE/BuChE inhibitor in scopolamine mouse model and inflammatory cells. Neuropharmacology 2017; 113(Pt A): 445-56. [3] Lam CS, Tipoe GL, Wong JK, Youdim MB, Fung ML. M30 antagonizes indoleamine 2, 3-dioxygenase activation and neurodegeneration induced by corticosterone in the hippocampus. PLoS One 2016; 11(11): e0166966. [4] Golko-Perez S, Amit T, Bar-Am O, Youdim MBH, Weinreb O. A novel iron chelator-radical scavenger ameliorates motor dysfunction and improves life span and mitochondrial biogenesis in SOD1G93A ALS mice. Neurotox Res 2017; 31(2): 230-44. [5] Lam C-S, Tipoe GL, Wong JK-C, Youdim MBH, Fung M-L. M30 antagonizes indoleamine 2,3-dioxygenase activation and neurodegeneration induced by corticosterone in the hippocampus. PLoS One 2016; 11(11): e0166966. [6] Shin E-J, Nam Y, Lee JW, et al. N-Methyl, N-propynyl-2-phenylethylamine (MPPE), a selegiline analog, attenuates MPTP-induced dopaminergic toxicity with guaranteed behavioral safety: Involvement of inhibitions of mitochondrial oxidative burdens and p53 gene-elicited pro-apoptotic change. Mol Neurobiol 2016; 53(9): 6251-69. [7] Youdim MBH, Van der Schyf CJ. Multifunctional drugs as neurotherapeutics. Neurotherapeutics 2009; 6: 1-213. [8] Youdim MBH, Edmondson D, Tipton KF. The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 2006; 7: 295-309. [9] Youdim MBH, Buccafusco JJ. Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol Sci 2005; 26: 27-35. [10] Tazik S, Johnson S, Lu D, et al. Comparative neuroprotective effects of rasagiline and aminoindan with selegiline on dexamethasone-induced brain cell apoptosis. Neurotox Res 2009; 15(3): 284-90.